ICAM-1 as a biomarker of efficacy for oncolytic coxsackievirus A21 in patient-derived Ewing sarcoma models
- 1Leeds Institute of Medical Research, University of Leeds, St James’s University Hospital, Wellcome Trust Brenner Building, Beckett Street, Leeds LS9 7TF, UK
Abstract
Ewing sarcoma (EWS) is a rare pediatric malignancy of the bone and soft tissue and requires better-tolerated and improved therapies. Oncolytic viruses (OVs) preferentially replicate in cancer cells, causing oncolysis, and activate both innate and adaptive anti-tumor immunity. Thus, OVs have the potential to generate long-lasting, systemic anti-cancer activity. Using a unique panel of patient-derived EWS cultures (PDES), recently derived from patient tumors at diagnosis and relapse, we have identified oncolytic coxsackievirus A21 (CVA21) as a candidate therapeutic OV in EWS, due to its high oncolytic activity and immune stimulation. PDES, unlike established EWS cell lines, expressed intercellular adhesion molecule-1 (ICAM-1), the CVA21 viral entry receptor, and were sensitive to CVA21-mediated oncolysis. Treatment with known ICAM-1 inducers, including tumor necrosis factor (TNF) and the clinically deliverable agent all-trans retinoic acid (ATRA), increased ICAM-1 expression and enhanced CVA21-induced oncolysis. Importantly, while CVA21 replication and oncolysis were inhibited by antiviral type I interferon, pre-treatment with ICAM-1 inducers (or CVA21-induced immune-mediated cytokines) overcame this inhibition. In addition to direct oncolysis, co-culture of CVA21-infected PDES with peripheral blood mononuclear cells (PBMCs) stimulated significant immune-mediated killing. This study presents pre-clinical evaluation of CVA21 using clinically relevant PDES samples and identifies CVA21 as a promising candidate for EWS immunotherapy.
Related
- Oncolytic viruses in combination cancer therapy: clinical lessons, biomarker-guided strategies, and future treatment directions
- Antiviral humoral immunity as biomarker and effector in oncolytic adenovirus TILT-123 therapy
- Lung FDG-PET is an early pharmacodynamic biomarker of antiviral efficacy in preclinical influenza
- Circulating hepatocyte-derived extracellular particles as potential biomarker of steatohepatitis progression to fibrogenesis: Exploring the impact of smoking
- Exosomes as biomarker-diagnostics and therapeutics for multiple sclerosis: promise, pitfalls, and the rising role of milk-derived exosomes, towards next-generation precision medicine
BibTeX
@article{baugh2026icam1,
title = {{ICAM-1 as a biomarker of efficacy for oncolytic coxsackievirus A21 in patient-derived Ewing sarcoma models}},
author = {Richard T. Baugh and Tyler Barr and Elizabeth A. Roundhill and Fay Ismail and Milene Volpato and Graham P. Cook and Susan A. Burchill and Fiona Errington-Mais},
journal = {Molecular Therapy Oncology},
year = {2026},
month = oct,
doi = {10.1016/j.omton.2026.201367},
url = {https://doi.org/10.1016/j.omton.2026.201367},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - ICAM-1 as a biomarker of efficacy for oncolytic coxsackievirus A21 in patient-derived Ewing sarcoma models
AU - Richard T. Baugh
AU - Tyler Barr
AU - Elizabeth A. Roundhill
AU - Fay Ismail
AU - Milene Volpato
AU - Graham P. Cook
AU - Susan A. Burchill
AU - Fiona Errington-Mais
PY - 2026
DA - 2026/10/14
JO - Molecular Therapy Oncology
DO - 10.1016/j.omton.2026.201367
UR - https://doi.org/10.1016/j.omton.2026.201367
AB - Ewing sarcoma (EWS) is a rare pediatric malignancy of the bone and soft tissue and requires better-tolerated and improved therapies. Oncolytic viruses (OVs) preferentially replicate in cancer cells, causing oncolysis, and activate both innate and adaptive anti-tumor immunity. Thus, OVs have the potential to generate long-lasting, systemic anti-cancer activity. Using a unique panel of patient-derived EWS cultures (PDES), recently derived from patient tumors at diagnosis and relapse, we have identified oncolytic coxsackievirus A21 (CVA21) as a candidate therapeutic OV in EWS, due to its high oncolytic activity and immune stimulation. PDES, unlike established EWS cell lines, expressed intercellular adhesion molecule-1 (ICAM-1), the CVA21 viral entry receptor, and were sensitive to CVA21-mediated oncolysis. Treatment with known ICAM-1 inducers, including tumor necrosis factor (TNF) and the clinically deliverable agent all-trans retinoic acid (ATRA), increased ICAM-1 expression and enhanced CVA21-induced oncolysis. Importantly, while CVA21 replication and oncolysis were inhibited by antiviral type I interferon, pre-treatment with ICAM-1 inducers (or CVA21-induced immune-mediated cytokines) overcame this inhibition. In addition to direct oncolysis, co-culture of CVA21-infected PDES with peripheral blood mononuclear cells (PBMCs) stimulated significant immune-mediated killing. This study presents pre-clinical evaluation of CVA21 using clinically relevant PDES samples and identifies CVA21 as a promising candidate for EWS immunotherapy.
SN - 2950-3299
ER -